Clinical Trials
28 trialsCASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
PREDICT
Alliance for Clinical Trials in Oncology
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
CHAMP
Duke University
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
CheckMate 650
Bristol-Myers Squibb
CATCH-177
Case Comprehensive Cancer Center
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
ACDC-RP
University Health Network, Toronto
AARDVARC
AstraZeneca
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cabazitaxel and Radiation For Patients With Prostate Cancer
Brown University
TACTIK
UNICANCER
CABA-V7
Erasmus Medical Center
CHROME
The Clatterbridge Cancer Centre NHS Foundation Trust
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
University of Colorado, Denver
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
Consorzio Oncotech
CARVE
Erasmus Medical Center
ConCab
Karolinska University Hospital
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
H. Lee Moffitt Cancer Center and Research Institute
SWITCH
Sanofi